



Active substances set

Search phrase: Liver cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer Lenvatinib w monoterapii jest wskazany w leczeniu NO REIMBURSEMENT dorosłych pacjentów z zaawansowanym lub nieoperacyjnym Lenvatinib rakiem wątrobowokomórkowym, którzy nie byli poddani wcześniej leczeniu ogólnemu. Tremelimumab in combination with durvalumab is indicated NO REIMBURSEMENT Tremelimumab for the first line treatment of adults with advanced or **ESMO** unresectable hepatocellular carcinoma (HCC). Hepatocellular carcinoma (HCC) Ipilimumab in combination NO REIMBURSEMENT with nivolumab is indicated for the first-line treatment of **Ipilimumab** adult patients with unresectable or advanced hepatocellular **ESMO** Hepatocellular carcinoma (HCC) Nivolumab in combination NO REIMBURSEMENT with ipilimumab is indicated for the first-line treatment of **Nivolumab** adult patients with unresectable or advanced hepatocellular **ESMO** carcinoma. REIMBURSEMENT Regorafenib is indicated as monotherapy for the treatment WITH RESTRICTIONS Regorafenib of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. **ESMO**

Cabozantinib

Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

0	REIMBURSEMENT
	WITH RESTRICTIONS



Ramucirumab

Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of \geq 400 ng/ml and who have been previously treated with sorafenib.

• REIMBURSEMENT
WITH RESTRICTIONS

ESMO

Atezolizumab

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

REIMBURSEMENT
WITH RESTRICTIONS

ESMO

Durvalumab

Hepatocellular Carcinoma (HCC) Durvalumab as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Durvalumab in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

REIMBURSEMENT
WITH RESTRICTIONS

